Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
Status:
Completed
Trial end date:
2021-01-13
Target enrollment:
Participant gender:
Summary
This phase I clinical trial studies vemurafenib with sorafenib tosylate or crizotinib in
treating patients with advanced malignancies with BRAF mutations. Sorafenib tosylate and
crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Sorafenib tosylate may also stop the growth of advanced malignancies by blocking
blood flow to tumors. Drugs used in chemotherapy, such as vemurafenib, work in different ways
to stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving vemurafenib together with sorafenib
tosylate or crizotinib may kill more cancer cells.